Chairman of the House Oversight Committee Rep. Elijah Cummings (D-MD) launched an investigation today into the drug pricing practices of 12 pharmaceutical companies. A number of companies named in the investigation saw their stock prices fall, including Amgen (NSDQ:AMGN), AbbVie (NYSE:ABBV), AstraZeneca (NYSE:AZN), Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO). A hearing is reportedly set for Jan. 29 and will include patients affected by rising […]
Bigfoot Biomedical inks insulin deal with Eli Lilly
Bigfoot Biomedical said today that it inked a non-exclusive deal with Eli Lilly (NYSE:LLY) to integrate Eli Lilly’s insulin products into Bigfoot’s investigational insulin delivery devices. The California-based company expects to launch its first two insulin delivery systems – Bigfoot Inject and Bigfoot Loop – in 2020, contingent upon finishing a pivotal trial and landing regulatory approvals. Get […]
Report: Pharma companies kick off new year with price hikes
Major pharmaceutical firms started the new year by hiking the prices of hundreds of drugs, according to a new study published by Rx Savings Solutions. First reported in The Wall Street Journal, the study found that the average price increase taken by more than three dozen companies was roughly 6.3%. Get the full story at our […]
Eli Lilly touts data for concentrated insulin delivered via Insulet’s Omnipod tech
Eli Lilly (NYSE:LLY) touted data this week from a Phase III study evaluating its Humulin R U-500 concentrated insulin delivered via Insulet‘s (NSDQ:PODD) investigational Omnipod U-500 device. The company reported that people with Type II diabetes taking Humulin R U-500 using the Omnipod device experienced greater A1c reductions and needed less daily insulin compared to adults using […]
Beta Bionics wins FDA nod for home-use trial of artificial pancreas tech
Beta Bionics said this week that it won FDA approval to start recruiting patients with Type I diabetes for home-use studies of its iLet bionic pancreas system. The trial is slated to test Novo Nordisk’s fast-acting insulin, Fiasp, with the company’s autonomous infusion pump in adults with Type I diabetes. The study will also evaluate […]
With groundbreaking approval, Amgen launches new class of medicine for migraine patients
Amgen (NSDQ:AMGN) won FDA approval this week for its once-monthly Aimovig injection designed to prevent the onset of migraines in adults. The drug is the first of its kind – a molecule that blocks the receptor for a protein that is linked to migraine pain, the calcitronin gene-related peptide. Other major pharmaceutical companies like Eli Lilly (NYSE:LLY) […]
HHS secretary calls on drug companies to ‘stop the price hikes’
After President Donald Trump’s drug pricing speech last week was deemed a “non-event” by analysts, all eyes turned to the secretary of the U.S. Dept. of Health & Human Services, Alex Azar, to see what the former pharma executive viewed as the administration’s top concerns. Azar called on the industry to “stop the price hikes” […]
Eli Lilly inks $63m deal with Sigilon to develop encapsulated cell therapies for diabetes
Eli Lilly (NYSE:LLY) plans to put $473 million on the table to fund a collaboration with Cambridge, Mass.-based startup Sigilon Therapeutics, the insulin-maker reported today. The goal of the newly-established partnership is to develop encapsulated cell therapies to treat Type I diabetes. Get the full story at our sister site, Drug Delivery Business News.
Dexcom CEO on ‘treading new ground’ with G6 glucose monitor
Kevin Sayer sold his first glucose sensor in 1994. More than twenty years later, the chief executive of Dexcom (NSDQ:DXCM) still believes that glucose-monitoring technology can transform the way patients manage their diabetes. This week, Dexcom won FDA approval for its latest continuous glucose monitor. The G6 system is the first of the company’s that does […]
Japan approves Novo Nordisk’s once-weekly Type II diabetes drug
The Japanese Ministry of Health, Labor and Welfare gave Novo Nordisk (NYSE:NVO) the green light to market its once-weekly type II diabetes drug, Ozempic, Reuters reported today. The pharma company’s drug, semaglutide, is a glucagon-like peptide-1 analog that mimics an intestinal hormone to trigger insulin production in people with diabetes. Get the full story at our sister site, Drug Delivery […]
Meet the insulin-makers and device companies developing smart insulin pens
The global market for connected insulin pens could be worth up to $123 million by 2023, according to a report published this year by Research & Markets. Insulin pens, designed for people who control their diabetes with multiple daily injections instead of a pump or wearable patch, are portable devices that were first introduced in 1985 with […]
- 1
- 2
- 3
- …
- 6
- Next Page »
MassDevice Network
@MassDevice
LinkedIn
YouTube